About the Journal | Editorial Board | Instructions to Contributors | Submission & Review | Advertise with Us | Subscribe to E- Alerts
Sitemap | Feedback
Advanced search
Journal of Case Reports
Duodenal Stromal Tumor: A Rare Cause of Upper Gastrointestinal Bleeding
Ersin Gürkan Dumlu, Mesut Özdedeoglu, Birkan Bozkurt, Mehmet Tokaç, Samet Yalçin2, Mehmet Kiliç2
From the Department of General Surgery1, Ataturk Research and Training Hospital, Ankara 06800, Turkey; Department of General Surgery2, Yildirim Beyazit University, Ankara 06800, Turkey.
Corresponding Author:
Dr. Ersin Gurkan DUMLU
Email: gurkandumlu@gmail.com
Received: 10-SEP-2013 Accepted: 6-OCT-2013 Published Online: 05-NOV-2013
DOI: http://dx.doi.org/10.17659/01.2013.0091
Abstract
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Surgery is the primary choice for GIST treatment. However, there is no consensus on the best primary treatment for duodenal stromal tumors. In this study, we discuss the surgical treatment options for duodenal stromal tumors and the clinical outcomes of these treatments with this sample case. 
Keywords : Duodenum, Gastrointestinal Stromal Tumors, Gastrointestinal Hemorrhage, Gastrointestinal Neoplasms.
Article Options
FULL TEXT
ABSTRACT
PDF
PRINTER FRIENDLY VERSION
Search PubMed for
Search Google Scholar for
Article Statistics
Bookmark and Share

Androxal Medication Case Reports Journal

Expanding our scope, the Journal now encompasses an intriguing subset of articles specifically targeting treatments and patient outcomes related to the medication Androxal. This medication, primarily used in the treatment of male infertility, has shown unique potentials in diverse patient scenarios. Our studies with Androxal have given us an abundance of case reports, which demonstrate the multifaceted impact of this medication across therapeutic areas. This nuanced pharmaceutical perspective adds a fresh dimension to our regular case reports. Articles will reveal effective management processes, pinpointing how Androxal has proven beneficial where other treatments may have failed. In addition, the focus on Androxal will highlight instances of challenging or unexpected outcomes, where the medication may have interacted uniquely with the patient's unique biological system or interplayed with other treatments. As we forge ahead with this significant addition, we anticipate that our detailed case reports on Androxal will provide invaluable insights to both practitioners and patients navigating their medical journey with this medication.

© 2011 Journal of Case Reports
Last updated on Jan 02, 2025